SG11201603165TA - Novel Peptide Having 4 Linked CTL Epitopes - Google Patents

Novel Peptide Having 4 Linked CTL Epitopes

Info

Publication number
SG11201603165TA
SG11201603165TA SG11201603165TA SG11201603165TA SG11201603165TA SG 11201603165T A SG11201603165T A SG 11201603165TA SG 11201603165T A SG11201603165T A SG 11201603165TA SG 11201603165T A SG11201603165T A SG 11201603165TA SG 11201603165T A SG11201603165T A SG 11201603165TA
Authority
SG
Singapore
Prior art keywords
ctl epitopes
novel peptide
linked ctl
linked
peptide
Prior art date
Application number
SG11201603165TA
Other languages
English (en)
Inventor
Satoshi Fukaya
Toshihiro Osada
Hiroshi Wada
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201603165TA publication Critical patent/SG11201603165TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201603165TA 2013-10-21 2014-10-20 Novel Peptide Having 4 Linked CTL Epitopes SG11201603165TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013218524 2013-10-21
JP2014155132 2014-07-30
PCT/JP2014/077807 WO2015060235A1 (ja) 2013-10-21 2014-10-20 新規ctlエピトープ4連結ペプチド

Publications (1)

Publication Number Publication Date
SG11201603165TA true SG11201603165TA (en) 2016-05-30

Family

ID=52992831

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201603165TA SG11201603165TA (en) 2013-10-21 2014-10-20 Novel Peptide Having 4 Linked CTL Epitopes

Country Status (19)

Country Link
US (1) US10137183B2 (da)
EP (1) EP3061771B1 (da)
JP (2) JP6211093B2 (da)
KR (1) KR101913333B1 (da)
CN (1) CN105658673B (da)
AU (1) AU2014337643B2 (da)
CA (1) CA2927817C (da)
DK (1) DK3061771T3 (da)
ES (1) ES2796301T3 (da)
HU (1) HUE050164T2 (da)
MX (1) MX2016004754A (da)
MY (1) MY179119A (da)
PH (1) PH12016500742B1 (da)
PL (1) PL3061771T3 (da)
PT (1) PT3061771T (da)
RU (1) RU2636549C1 (da)
SG (1) SG11201603165TA (da)
TW (1) TWI651094B (da)
WO (1) WO2015060235A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926944B (zh) * 2015-05-22 2018-04-13 北京康爱瑞浩生物科技股份有限公司空港分公司 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途
CN112135908A (zh) * 2018-01-22 2020-12-25 国立传染病研究所长代表日本国 选择性cd8阳性t细胞诱导疫苗抗原
EP3815711A4 (en) * 2018-06-29 2022-08-10 Taiho Pharmaceutical Co., Ltd. ANTITUMOR AGENT AND ITS METHOD OF EVALUATION
WO2020091040A1 (ja) * 2018-11-02 2020-05-07 大鵬薬品工業株式会社 エマルジョン製剤及びその調製方法
EP4082563A4 (en) * 2019-12-26 2024-02-28 Taiho Pharmaceutical Co., Ltd. POST-OPERATIVE ADJUVANT THERAPY AGENT

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US20080286228A1 (en) 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
CN1330377C (zh) 1996-03-10 2007-08-08 明治乳业株式会社 用于治疗变态反应疾病的基于肽的免疫治疗剂
JP4138073B2 (ja) * 1998-05-08 2008-08-20 株式会社グリーンペプタイド ヒト癌退縮抗原タンパク質
EP1090924B8 (en) 1998-06-25 2007-11-21 Green Peptide Co., Ltd. Tumor antigen peptides originating in cyclophilin b
DE69939833D1 (de) 1998-08-28 2008-12-11 Kyogo Itoh Neues tumor-antigen-protein sart-3 und tumor-antigen-peptid davon
US6667037B1 (en) 1998-10-09 2003-12-23 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1207199B1 (en) * 1999-08-05 2010-04-14 Green Peptide Co., Ltd. Tumor antigen
EP1222274A2 (en) 1999-10-19 2002-07-17 Ludwig Institute For Cancer Research Mage-a12 antigenic peptides and uses thereof
WO2001041741A1 (en) 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
WO2002010396A1 (en) * 2000-07-28 2002-02-07 Mogam Biotechnology Research Institute Gene expression system for mass production of hepatitis c viral rna-dependent rna polymerase and enzyme assay using fusion protein expressed therefrom
JP4900884B2 (ja) * 2000-07-31 2012-03-21 株式会社グリーンペプタイド 腫瘍抗原
JP4097178B2 (ja) 2000-10-03 2008-06-11 株式会社グリーンペプタイド 腫瘍抗原
CA2476995A1 (en) 2001-09-18 2003-03-27 Kyogo Itoh Method of detecting cellular immunity and application thereof to drugs
ATE441713T1 (de) 2002-09-27 2009-09-15 Dainippon Sumitomo Pharma Co Tumorantigenprotein und dessen verwendung
WO2005041981A1 (en) * 2003-10-31 2005-05-12 Kurume University Combination therapy of peptide vaccination and estramustine treatment
JP4579581B2 (ja) * 2003-12-08 2010-11-10 株式会社グリーンペプタイド 副甲状腺ホルモン関連タンパク質のhla−a24またはhla−a2結合ペプチド
EP1712620A4 (en) 2004-01-23 2008-05-28 Greenpeptide Co Ltd PEPTIDE FROM EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
EP1767541A4 (en) * 2004-05-26 2008-10-22 Greenpeptide Co Ltd HLA-A24 OR HLA-A2-RELATED PEPTIDE OF PARATHORMONE-RELATED PROTEIN
JP4547197B2 (ja) 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
JP2006188507A (ja) 2004-12-10 2006-07-20 Tokyo Univ Of Agriculture & Technology 蛋白質の溶解度向上方法
PT1961761E (pt) 2005-11-30 2010-12-16 Chugai Pharmaceutical Co Ltd Novos compostos peptídicos do tumor de wilms
JP5114403B2 (ja) 2006-07-11 2013-01-09 株式会社グリーンペプタイド Hla−a3スーパータイプアレル陽性前立腺癌患者に対する癌ワクチン療法に有用なsart3由来ペプチド
JP2008145715A (ja) * 2006-12-08 2008-06-26 Fujifilm Corp ポジ型感光性組成物、パターン形成方法、及び薄膜トランジスタアレイ基板
WO2009022652A1 (ja) * 2007-08-16 2009-02-19 Kurume University HLA-A3スーパータイプアレル陽性癌患者に対する癌ワクチン療法に有用なLck由来ペプチド
GB0717864D0 (en) 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
EP2801367B1 (en) 2007-09-18 2017-04-19 Green Peptide Co., Ltd. CTL inducer composition
JP5706895B2 (ja) 2010-07-07 2015-04-22 株式会社グリーンペプタイド がんペプチドワクチン
JP5911098B2 (ja) 2012-04-09 2016-04-27 国立研究開発法人情報通信研究機構 翻訳装置、およびプログラム
JP2014155132A (ja) 2013-02-13 2014-08-25 Murata Mfg Co Ltd 回路基板およびその製造方法
MX2015011257A (es) * 2013-03-08 2015-11-16 Taiho Pharmaceutical Co Ltd Peptido novedoso que tiene 5 epitopos de linfocitos t citotoxicos enlazados.

Also Published As

Publication number Publication date
CA2927817C (en) 2019-02-26
US10137183B2 (en) 2018-11-27
DK3061771T3 (da) 2020-07-13
TW201601749A (zh) 2016-01-16
JP2017171678A (ja) 2017-09-28
PH12016500742A1 (en) 2016-06-20
CN105658673B (zh) 2019-07-26
CN105658673A (zh) 2016-06-08
AU2014337643B2 (en) 2017-07-13
PL3061771T3 (pl) 2020-10-19
JPWO2015060235A1 (ja) 2017-03-09
JP6211093B2 (ja) 2017-10-11
EP3061771A4 (en) 2017-08-16
EP3061771A1 (en) 2016-08-31
CA2927817A1 (en) 2015-04-30
WO2015060235A1 (ja) 2015-04-30
EP3061771B1 (en) 2020-04-15
TWI651094B (zh) 2019-02-21
KR20160055922A (ko) 2016-05-18
PT3061771T (pt) 2020-05-06
PH12016500742B1 (en) 2016-06-20
AU2014337643A1 (en) 2016-05-19
HUE050164T2 (hu) 2020-12-28
MY179119A (en) 2020-10-28
KR101913333B1 (ko) 2018-10-30
MX2016004754A (es) 2016-07-22
RU2636549C1 (ru) 2017-11-23
ES2796301T3 (es) 2020-11-26
US20160235828A1 (en) 2016-08-18
BR112016008254A2 (pt) 2017-09-26

Similar Documents

Publication Publication Date Title
HK1216757A1 (zh) 肽化合物
EP2981543A4 (en) Novel 4 7 peptide antagonists
EP2949750A4 (en) ANTIBODY-BINDING PEPTIDE
EP2976353A4 (en) AUTOPHAGYINDUCTING PEPTIDE ANALOG
HRP20180452T1 (hr) Peptidi
SG11201603165TA (en) Novel Peptide Having 4 Linked CTL Epitopes
HK1211596A1 (en) Peptide
HK1215440A1 (zh) 新型的具有 個連接的 表位的肽
HK1211595A1 (en) Peptide
HK1198769A1 (en) Novel peptide
GB201315130D0 (en) Peptides
IL244956B (en) New peptide compositions
GB201305465D0 (en) Novel peptides
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides